ABL Bio Advances EGFR x MUC1 ADC ABL209 Toward Phase 1 With Differentiated Design

According to a recent LinkedIn post from BioSpectator Inc, South Korean biotech firm ABL Bio is advancing its EGFR x MUC1 bispecific antibody-drug conjugate ABL209 (also referenced as NEOK002) toward first dosing in a Phase 1 trial in the second quarter. The post highlights disclosures made at AACR 2026 regarding the drug’s structure, payload choice, and differentiated targeting strategy.

The company’s LinkedIn post explains that ABL209 combines a “1+1” EGFR/MUC1 bispecific antibody with a TOP1 inhibitor payload called tevatecan, the same payload used in the CLDN18.2 ADC IBI343, which has shown antitumor activity and dose escalation up to 6 mpk without observed interstitial lung disease in clinical studies. ABL Bio’s researcher reportedly emphasized that ABL209’s design aims to reduce EGFR-related toxicity by lowering EGFR binding affinity roughly 60-fold compared with marketed EGFR antibodies.

According to the summary, the post also notes that ABL209 targets a different domain of MUC1 than prior MUC1-directed drugs, which have often failed in clinical development due to efficacy loss when segments of MUC1 are shed in the tumor microenvironment. Based on this design rationale, the LinkedIn content points to three key nonclinical data sets supporting ABL209’s competitiveness, with results published in Molecular Cancer Therapeutics.

For investors, this post suggests ABL Bio is positioning ABL209 as a next-generation oncology ADC candidate with a potentially improved therapeutic window and differentiated target engagement, which could enhance the value of its pipeline if early safety and efficacy readouts are positive. The reference to peer payload performance and publication in a reputable journal may bolster perceived scientific credibility, though eventual financial impact will depend on clinical trial outcomes, partnering activity, and competitive dynamics in the EGFR/MUC1 and broader ADC markets.